Intervention Review

You have free access to this content

Inhaled hyperosmolar agents for bronchiectasis

  1. Anna Hart1,
  2. Karnam Sugumar2,
  3. Stephen J Milan3,*,
  4. Stephen J Fowler4,5,
  5. Iain Crossingham6

Editorial Group: Cochrane Airways Group

Published Online: 12 MAY 2014

Assessed as up-to-date: 2 APR 2014

DOI: 10.1002/14651858.CD002996.pub3


How to Cite

Hart A, Sugumar K, Milan SJ, Fowler SJ, Crossingham I. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD002996. DOI: 10.1002/14651858.CD002996.pub3.

Author Information

  1. 1

    Lancaster University, Lancaster Medical School, Clinical Research Hub, Lancaster, Lancashire, UK

  2. 2

    Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Department of Paediatrics, Preston, UK

  3. 3

    St George's, University of London, Population Health Sciences and Education, London, UK

  4. 4

    University Hospital of South Manchester, University of Manchester, NIHR Respiratory and Allergy Clinical Research Facility, Manchester, UK

  5. 5

    Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK

  6. 6

    Royal Blackburn Hospital, Blackburn, Lancashire, UK

*Stephen J Milan, Population Health Sciences and Education, St George's, University of London, London, UK. s.milan@lancaster.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 12 MAY 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Inhaled mannitol versus placebo, Outcome 1 Change from baseline in health-related quality of life (SGRQ). Total.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Inhaled mannitol versus placebo, Outcome 2 Change from baseline in health-related quality of life (SGRQ). Symptoms.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Inhaled mannitol versus placebo, Outcome 3 Change from baseline in health-related quality of life (SGRQ). Activity.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Inhaled mannitol versus placebo, Outcome 4 Change from baseline in health-related quality of life (SGRQ). Impact.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Inhaled mannitol versus placebo, Outcome 5 Leicester Cough Questionnaire score after 12 weeks.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Inhaled mannitol versus placebo, Outcome 6 Bronchiectasis Symptoms Questionnaire score at week 12.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Inhaled mannitol versus placebo, Outcome 7 Change in FEV1 (% predicted).
[Analysis 1.8]
Analysis 1.8. Comparison 1 Inhaled mannitol versus placebo, Outcome 8 FEV1 (L) at 12 weeks.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Inhaled mannitol versus placebo, Outcome 9 Adverse events.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Inhaled mannitol versus placebo, Outcome 10 FEF25-75(L/s) after 12 weeks.
[Analysis 1.11]
Analysis 1.11. Comparison 1 Inhaled mannitol versus placebo, Outcome 11 Change in 24 hr sputum weight from baseline.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Inhaled mannitol versus placebo, Outcome 12 Antibiotic use.
[Analysis 1.13]
Analysis 1.13. Comparison 1 Inhaled mannitol versus placebo, Outcome 13 Incremental Shuttle Walk (metres) at week 12.
[Analysis 1.14]
Analysis 1.14. Comparison 1 Inhaled mannitol versus placebo, Outcome 14 FVC (L) at 12 weeks.
[Analysis 1.15]
Analysis 1.15. Comparison 1 Inhaled mannitol versus placebo, Outcome 15 Serious adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Hypertonic saline versus isotonic saline, Outcome 1 SGRQ Symptom.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Hypertonic saline versus isotonic saline, Outcome 2 SGRQ Activity.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Hypertonic saline versus isotonic saline, Outcome 3 SGRQ Impact.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Hypertonic saline versus isotonic saline, Outcome 4 Leicester Cough Questionnaire Physical.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Hypertonic saline versus isotonic saline, Outcome 5 Leicester Cough Questionnaire Psychological.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Hypertonic saline versus isotonic saline, Outcome 6 Leicester Cough Questionnaire Social.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Hypertonic saline versus isotonic saline, Outcome 7 FEV1 (L).
[Analysis 2.8]
Analysis 2.8. Comparison 2 Hypertonic saline versus isotonic saline, Outcome 8 FVC.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Hypertonic saline versus isotonic saline, Outcome 9 FEF25-75.
[Analysis 2.10]
Analysis 2.10. Comparison 2 Hypertonic saline versus isotonic saline, Outcome 10 Adverse events.